SCM
LXEO icon

Suvretta Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Suvretta Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.7M Buy
6,384,200
+5,134,200
+411% +$27.8M 0.54% 46
2026
Q1 		$7.17M Hold
1,250,000
– – 0.18% 51
2025
Q4 		$12.4M Buy
+1,250,000
New +$11.4M 0.25% 60

Other funds holding LXEO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Suvretta Capital Management's LXEO Position: Q2 2026 in Review

Suvretta Capital Management increased its Lexeo Therapeutics (LXEO) stake by 411% in Q2 2026, buying an estimated $27.8M and bringing the position to 6,384,200 shares worth $29.7M. The position accounts for 0.54% of the portfolio, ranked #46.

Suvretta Capital Management first reported a position in LXEO in Q4 2025 and has held it in 3 quarters since. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Suvretta Capital Management held 6,384,200 shares of Lexeo Therapeutics worth $29.7M as of Q2 2026.
  • Suvretta Capital Management bought 5,134,200 Lexeo Therapeutics shares in Q2 2026, an estimated $27.8M.
  • Lexeo Therapeutics made up 0.54% of Suvretta Capital Management's portfolio in Q2 2026, its #46 holding.
  • Suvretta Capital Management first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.